These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. A new hope in immunotherapy for malignant gliomas: adoptive T cell transfer therapy. Chung DS; Shin HJ; Hong YK J Immunol Res; 2014; 2014():326545. PubMed ID: 25009822 [TBL] [Abstract][Full Text] [Related]
43. In situ dendritic cell vaccination for the treatment of glioma and literature review. Li M; Han S; Shi X Tumour Biol; 2016 Feb; 37(2):1797-801. PubMed ID: 26318301 [TBL] [Abstract][Full Text] [Related]
45. Immunobiology of brain tumors. Sawamura Y; de Tribolet N Adv Tech Stand Neurosurg; 1990; 17():3-64. PubMed ID: 2180410 [TBL] [Abstract][Full Text] [Related]
46. Importance of immune monitoring approaches and the use of immune checkpoints for the treatment of diffuse intrinsic pontine glioma: From bench to clinic and vice versa (Review). Scutti JAB Int J Oncol; 2018 Apr; 52(4):1041-1056. PubMed ID: 29484440 [TBL] [Abstract][Full Text] [Related]
47. Immunologic approaches to therapy for brain tumors. Paul DB; Kruse CA Curr Neurol Neurosci Rep; 2001 May; 1(3):238-44. PubMed ID: 11898524 [TBL] [Abstract][Full Text] [Related]
48. Mechanisms of local immunoresistance in glioma. Albesiano E; Han JE; Lim M Neurosurg Clin N Am; 2010 Jan; 21(1):17-29. PubMed ID: 19944963 [TBL] [Abstract][Full Text] [Related]
49. Immunotherapy of malignant gliomas. Maleci A J Neurosurg Sci; 1989; 33(1):77-82. PubMed ID: 2674361 [TBL] [Abstract][Full Text] [Related]
50. Immunomonitoring in glioma immunotherapy: current status and future perspectives. Lamano JB; Ampie L; Choy W; Kesavabhotla K; DiDomenico JD; Oyon DE; Parsa AT; Bloch O J Neurooncol; 2016 Mar; 127(1):1-13. PubMed ID: 26638171 [TBL] [Abstract][Full Text] [Related]